The Dose Dependent Effects of Ruxolitinib on the Invasion and Tumorigenesis in Gliomas Cells via Inhibition of Interferon Gamma-Depended JAK/STAT Signaling Pathway

Emre Delen,¹ Oğuzhan Doğanlar²

¹Department of Neurosurgery, Trakya University School of Medicine, Edirne, Turkey
²Department of Medical Biology, Trakya University School of Medicine, Edirne, Turkey

Objective: Glioblastoma multiforme (GBM) is the most aggressive form of brain tumor and treatment often fails due to the invasion of tumor cells into neighboring healthy brain tissues. Activation of the Janus kinase-signal transducer and activator of transcription (JAK/STAT) signaling pathway is essential for normal cellular function including angiogenesis, and has been proposed to have a pivotal role in glioma invasion. This study aimed to determine the dose-dependent effects of ruxolitinib, an inhibitor of JAK, on the interferon (IFN)-γ/IFN-α/IFN-β receptor/STAT and IFN-γ/IFN-γ receptor/STAT1 axes of the IFN-receptor-dependent JAK/STAT signaling pathway in glioblastoma invasion and tumorigenesis in U87 glioblastoma tumor spheroids.

Methods: We administered three different doses of ruxolitinib (50, 100, and 200 nM) to human U87 glioblastoma spheroids and analyzed the gene expression profiles of IFNs receptors from the JAK/STAT pathway. To evaluate activation of this pathway, we quantified the phosphorylation of JAK and STAT proteins using Western blotting.

Results: Quantitative real-time polymerase chain reaction analysis demonstrated that ruxolitinib led to upregulated of the IFN-α and IFN-γ while no change on the hypoxia-inducible factor-1α and vascular endothelial growth factor expression levels. Additionally, we showed that ruxolitinib inhibited phosphorylation of JAK/STAT proteins. The inhibition of IFNs dependent JAK/STAT signaling by ruxolitinib leads to decreases of the U87 cells invasiveness and tumorigenesis. We demonstrate that ruxolitinib may inhibit glioma invasion and tumorigenesis through inhibition of the IFN-induced JAK/STAT signaling pathway.

Conclusion: Collectively, our results revealed that ruxolitinib may have therapeutic potential in glioblastomas, possibly by JAK/STAT signaling triggered by IFN-α and IFN-γ.

Key Words: Ruxolitinib · Glioblastoma · Carcinogenesis · Interferons · Signal transduction.
INTRODUCTION

Glioblastoma multiforme (GBM) is the type of the brain cancer that is associated with the extremely deadly with the worst prognosis. The 5-year survival rate of GBM is <5%, and the prognosis remains poor at the present time despite recent advances in neurosurgical treatment options\(^2\). This is mainly attributed to the invasion of glioma cells into neighboring regions of normal brain tissue\(^24,28\). The presence of marginal regions with low glioma-cell density contribute to the failure of complete resection and subsequent recurrence of tumors, as detection of the margins through magnetic resonance imaging may be inaccurate\(^1,29\). The invasive behavior of GBM is thought to be a complex molecular process involving cellular angiogenesis signaling. Activation of the Janus kinase-signal transducer and activator of transcription (JAK/STAT) signaling pathway, which is a known oncogenic pathway related to angiogenesis, has been reported to play a pivotal role in GBM invasion\(^1\).

Ruxolitinib is an inhibitor of JAK1 and JAK2, and is used in routine clinical practice\(^8\). According to recent studies, ruxolitinib has antitumor effects in various human cancers including ovarian, metastatic pancreatic, tamoxifen-resistant breast, and metastatic colorectal cancer\(^9,12,14\). Ruxolitinib has also been found to decrease the expression of p-JAK2, vascular endothelial growth factor (VEGF), and hypoxia-inducible factor (HIF)-1\(\alpha\), thereby suppressing blood vessel formation in myeloproliferative neoplasms\(^4\). Previous studies have also shown that ruxolitinib inhibits STAT3, which is regulated by interferon (IFN), among patients with Sjögren syndrome\(^3\). Thus, treatments that focus on the inhibition of IFNs dependent JAK/STAT signaling through administration of ruxolitinib could have utility in attenuating glioma invasion.

Our pervious study demonstrated that ruxolitinib significantly inhibits the interleukin (IL)-6 receptor complex, which is dependent on the JAK2/STAT3 axis, at the gene expression level. Furthermore, microRNA-17 and microRNA-20a were found to be affected by ruxolitinib, and may be involved in the regulation of U87 glioma cell invasion\(^6\). In the present study, we investigated the possible effect of increasing doses of ruxolitinib on IFN-\(\alpha\) and IFN-\(\gamma\) receptor downstream of JAK/STAT signaling in human glioblastoma U87 tumor spheres, which is an in vitro model of tumor tissue\(^32\).

MATERIALS AND METHODS

Chemicals

Ruxolitinib (CAS 941678-49-5) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Methyl cellulose, (product number : M7027) for the tumor sphere assay and radioimmunoprecipitation assay (RIPA) Lysis Buffer System (sc-24948) were obtained from Sigma Aldrich (St. Louis, MO, USA) and Santa Cruz Biotechnology, respectively. The Pure-Link® RNA Mini Kit (Life Technologies, Grand Island, NY, USA), High-Capacity cDNA Reverse Transcription Kit (Life Technologies), TaqMan™ Universal PCR Master Mix (Life Technologies), and molecular grade water were obtained from Thermo Fisher Scientific (Rochester, NY, USA).

Antibodies

The antibodies that were used in this study were Phospho-JAK2 (Tyr1007, Tyr1008), JAK1 antibody (EPR349[N]) (ab133666), and Phospho-JAK1 (phospho-Y1022 + Y1023) antibody (EPR1899[2]) (ab138005) (Abcam, Cambridge, UK); Phospho-Jak2 [p Tyr1007, p Tyr1008] antibody, STAT3 (232209) antibody, and Phospho-STAT3 (Tyr705) antibody (Novus Bio., Cambridge, UK); SOCS7 antibody (PA5-44102), JAK2 monoclonal antibody (691R5), and actin monoclonal antibody (ACTN05 [C4]) (Thermo Fisher Scientific). Secondary horse-radish peroxidase (HRP)-linked anti-mouse and anti-rabbit IgG antibodies were supplied in the Western Breeze™ Chemiluminescent Kit (Thermo Fisher Scientific).

Cell line, culture conditions, and generation of spheroids

Established cell lines that are commercially available does not require Institutional Review Board approval. Glioblastoma cells, U-87 MG (ATCC® HTB-14™; American Type Culture Collection, Manassa, CO, USA), were cultured in American Type Culture Collection (ATCC)-formulated Eagle's Minimum Essential Medium (EMEM; Catalog No. 30-2003) supplemented with 10% fetal bovine serum (Gibco Life Technologies, Grand Island, NY, USA), 1 mM glutamine (Gibco Life Technologies) and 1% (final concentration) penicillin/streptomycin (Invitrogen, Carlsbad, CA, USA) complete EMEM media. Cells were kept in a humidified incubator at 37°C and 5% CO\(_2\) during the entire study. Tumor spheroids
were generated using the hanging-drop method with minor modifications. Single-cell suspensions were generated from trypsinized monolayers and diluted to the desired cell density using complete EMEM media supplemented with 0.5% methylcellulose. The, 20 µL of cell suspension was pipetted into 40 drops (final concentration of 750–1000 cells per drop) that were on a nonadherent, bacterial-grade polystyrene Petri dishes. The upper lids of the Petri dishes, with the tumor droplets, were inverted and 2 mL of phosphate-buffered saline placed in the lower dish. Dishes were incubated for 72 hours after which, spheroid formation was observed using an inverted microscope (ZEISS Axio Vert.A1, Oberkochen, Germany). All spheroids are collected into 15 mL Falcon tubes. Fresh spheroids of the same age were used in all experiments.

Matrigel invasion assay
For the invasion assay, 40 µL of collected spheroid solution, 100 µL matrigel matrix (Corning, Corning, NY, USA), and 100 µL collagen type I (Sigma Aldrich) were mixed in pre-chilled Eppendorf tubes and 40 µL of this mixture was plated into six wells of a 24-well plate that had previously been coated with Matrigel. This process was repeated until the desired number of groups was reached. The plate was incubated at 37°C in 5% CO₂ to allow the 3D scaffold to polymerize. Then, 1 mL of cell culture medium was added to each well. After 24 hours, tumor spheroids were treated with either vehicle or 50, 100, or 200 nM ruxolitinib for 48 hours. Five replicates were performed for each treatment, and duplicate experiments were performed. After 48 hours of treatment, cell invasion was recorded for 48 hours using an inverted phase-contrast light microscope (ZEISS Axio Vert.A1) equipped with digital camera.

Isolation of RNA, reverse transcription and quantitative real-time polymerase chain reaction
Total RNA was isolated from single spheroids of each group (five replicates) using RNA purification kit (Thermo Fisher Scientific). The cDNAs were synthesized using a High-Capacity cDNA Reverse Transcription Kit, according to kit protocols. Quantitative real-time polymerase chain reaction (qRT-PCR) analysis was performed on a Quant studio 5 real-time PCR (Life Technologies) using both TaqMan™ Universal PCR Master Mix and FastStart TaqMan® Probe Master (Life Technologies). The thermal cycling program and oligonucleotide primers are detailed in Table 1. Relative expressions levels were calculated using the comparative cycle threshold $(2^{−\Delta\Delta C_{t}})$ method with ribosomal RNA 18S for mRNA used as internal control.

Western blot assay
After ruxolitinib or vehicle treatment, 20 spheroids were homogenized for each replicate by subjecting to three cycles in the Daihan 15D high speed homogenizer (27000 rpm) with 5-minute intervals in 500 µL of ice-cold RIPA lysis buffer supplemented with 2 µL phenylmethylsulphonyl fluoride solution, 2 µL sodium orthovanadate solution, and 2 µL protease inhibitor cocktail solution (RIPA Lysis Buffer System, sc-24948; Santa Cruz Biotechnology). The resulting homogenate was centrifuged at 14000×g for 20 minutes and approximately 0.67–1.36 mg/mL total protein was determined from the A280 measurement recorded using a micro-volume spectrophotometer (Optizen Nano Q; Mecasys, Daejeon, Korea). Proteins were denatured then loaded onto a NuPAGE® Bis-Tris polyacrylamide gel (10%), electrophoresed, and transferred to
RESULTS

Ruxolitinib inhibits tumor invasion and tumorigenesis of human glioblastoma tumor spheroids

Examination of the effects of ruxolitinib on tumor spheroid growth and invasion were evaluated from the course of 3D spheroids recorded over 48 hours after the addition of ruxolitinib. As shown in Fig. 1A and B, all concentrations of ruxolitinib led to a dose-dependent decrease in invasion rate, while tumor inhibition was only significant after treatment with 200 nM ruxolitinib. These results indicate that ruxolitinib specifically the tumor invasion properties of glioblastoma cancer spheroids. Investigations of the effect of ruxolitinib on spheroid formation, an in vitro model of tumorigenesis, revealed clear tumor formation in the control group, but spheroid formation was visibly impaired in all ruxolitinib-treated groups 48 hours after drug administration (Fig. 1C).

Table 1. Gene ID, universal names of gene and Taq-Man Assay IDs

| Gene      | Name                                      | Taq-Man Assay ID | qRT-PCR condition                                                                 |
|-----------|-------------------------------------------|-----------------|-----------------------------------------------------------------------------------|
| IFN-1     | Type I interferon                         | Hs03044218_g1   | 1 cycle of 2 minutes at 50°C and 10 minutes at 95°C followed by 42 cycles of denaturation at 95°C for 15 seconds, annealing and extension at 60°C for 1 minute |
| IFNAR1    | Interferon alpha and beta receptor subunit 1 | Hs01066116_m1   |                                                                                   |
| IFNAR2    | Interferon alpha and beta receptor subunit 2 | Hs01022060_m1   |                                                                                   |
| IFN-γ     | Interferon gamma                          | Hs00989291_m1   |                                                                                   |
| IFN-γR1   | ligand-binding chain (alpha) of the gamma interferon receptor1 | Hs00166223_m1 |                                                                                   |
| IFN-γR2   | ligand-binding chain (alpha) of the gamma interferon receptor2 | Hs00194264_m1 |                                                                                   |
| JAK1      | Janus Kinase 1                            | Hs01026983_m1   |                                                                                   |
| JAK2      | Janus Kinase 2                            | Hs01078136_m1   |                                                                                   |
| STAT1     | Signal transducer and activator of transcription 1 | Hs01014008_m1 |                                                                                   |
| STAT2     | Signal transducer and activator of transcription 2 | Hs01013123_m1 |                                                                                   |
| STAT3     | Signal transducer and activator of transcription 3 | Hs01051738_g1 |                                                                                   |
| STAT4     | Signal transducer and activator of transcription 4 | Hs01028017_m1 |                                                                                   |
| SOCS 3    | Suppressor of cytokine signaling 3        | Hs02330328_s1   |                                                                                   |
| SOCS 5    | Suppressor of cytokine signaling 5        | Hs05012989_g1   |                                                                                   |
| SOCS 7    | Suppressor of cytokine signaling 7        | Hs00322554_m1   |                                                                                   |
| HIF1-α    | Hypoxia inducible factor 1 alpha subunit  | Hs00153153_m1   |                                                                                   |
| HIF1-β    | Hypoxia-inducible factor 1, beta subunit  | Hs01121918_m1   |                                                                                   |
| VEGF      | Vascular endothelial growth factor        | Hs00900055_m1   |                                                                                   |
| 18S rRNA  | Eukaryotic 18S rRNA                       | Hs03003631_g1   |                                                                                   |

qRT-PCR: quantitative real-time polymerase chain reaction

Polyvinylidene difluoride (PVDF) membranes (Life Technologies). The membranes were incubated in 5% milk in tris-buffered saline buffer. Antibodies were diluted in antibody binding buffer according to band intensity and incubated overnight in dark-room conditions (+4°C) and then incubated with secondary antibody solution containing anti-mouse IgG-HRP and anti-rabbit IgG-HRP for 1 hour. Protein bands of washed and enhanced immunoblots were observed using a chemiluminescence Micro ChemiDoc (DNR Bio-Imaging System Ltd., Jerusalem, Israel) gel imaging system. Bands were quantified using GelQuant software (DNR Bio-Imaging System Ltd.).

Statistical analysis

The differences in invasion rate and tumor volume, as well as the relative fold change in gene was compared between control and experimental groups by one-way analysis of variance, Tukey honestly significant difference test. Statistical analyses were performed using SPSS ver. 20 software (IBM, Chicago, IL, USA) with the significance level set at \( p \leq 0.05 \).
Fig. 1. A: Tumour volume and invasion rate of 50, 100, and 200 nM ruxolitinib treated and untreated (control) U87 spheroids. B: Relative % of tumour inhibition and relative % of invasion area in control and experimental groups at 48 hours. C: Images belongs to sphere formation assay. Values expressed as mean±standard error (n=5). *Indicates significantly different values compared to control groups (one-way analysis of variance, Tukey honestly significant difference test : p≤0.05). †p≤0.01. ‡p≤0.001. §p<0.0001.
**Fig. 2.** The relative expression level of genes belongs to IFN-I and IFN-γ receptors depended JAK/STAT pathway and related downstream signalling in 50, 100, and 200 nM ruxolitinib treated and untreated (control) U87 spheroids. All data normalized with ribosomal RNA 18S levels. Values expressed as mean±standard error (n=5). *Indicates significantly different values compared to control groups (one-way analysis of variance, Tukey honestly significant difference test: p≤0.05). †p≤0.01. ‡p≤0.001. §p<0.0001. IFN: interferon, JAK/STAT: Janus kinase-signal transducer and activator of transcription.
Ruxolitinib impairs IFN-α and IFN-γ-related JAK/STAT signaling in a glioblastoma model

Investigation of the mRNA levels of IFNAR1 and IFNAR2 revealed that ruxolitinib treatment caused significant upregulation of IFN-I and IFNAR2, but significant downregulation of IFNAR1 expression (Fig. 2). Ligation of IFN to IFNAR brings the receptor-associated kinases, JAK1 and Tyk2, in proximity to the receptor complex leading to phosphorylation of this complex and activation of downstream JAK/STAT signaling via the STAT1/STAT2 way. We observed dose-dependent over-expression of JAK1 and STAT1 in response to all concentrations of ruxolitinib. Furthermore, STAT2 expression increased significantly, although this was not dose dependent. From qRT-PCR analysis, we discovered that ruxolitinib treatment caused no significant change in STAT3 expression, while STAT4 was significantly upregulated by treatment with 200 nM ruxolitinib. With regards to type 2 IFNs and IFN-γ-receptor-dependent JAK/STAT signaling, we observed a significant increase in IFN-γ in response to 200 nM ruxolitinib, but no statistical differences were detected in the expression of IFN-γ receptors or JAK2 compared with the control (Fig. 2).

Suppressor of cytokine signaling proteins are potent JAK inhibitors. Administration of ruxolitinib at low doses caused upregulation of the suppressor of cytokine signalling (SOCS) 3. There was no statistically significant difference in SOCS5 or SOCS7 expression compared with the control. However, 200 nM ruxolitinib caused suppression of SOCS3 expression, while expression of SOCS5 and SOCS7 were statistically significant (Fig. 3). Tumor hypoxia is a primary mechanism of tumor-volume increase and angiogenesis. For this reason, we investigated HIF-1α and HIF-1β and VEGF expressions which are the key roles in tumor hypoxia and angiogenesis. Expression of HIF-1β was unchanged by ruxolitinib administration at any concentration, while HIF-1α and VEGF were significantly upregulated in response to low-dose ruxolitinib, but were not significantly different compared with the control group after treatment with 200 nM ruxolitinib.

![Graphs showing the relative expression levels of SOCS3, SOCS5, SOCS7, HIF-1α, HIF-1β, and VEGF in response to different concentrations of ruxolitinib.](https://doi.org/10.3340/jkns.2019.0252)

**Fig. 3.** The relative expression level of genes belongs to hypoxia related angiogenesis (HIF1-α, HIF1-β, and VEGF) and specific JAK inhibitors SOCS family signalling in 50, 100, and 200 nM ruxolitinib treated and untreated (control) U87 spheroids. All data normalized with ribosomal RNA 18S levels. Values expressed as mean±standard error (n=5). *Indicates significantly different values compared to control groups (one-way analysis of variance, Tukey honestly significant difference test: p≤0.05). †p≤0.01. ‡p≤0.001. §p<0.0001. SOCS: the suppressor of cytokine signalling, HIF: hypoxia-inducible factor, VEGF: vascular endothelial growth factor, JAK: Janus kinase-signal transducer.
200 nM ruxolitinib (Fig. 3).

Ruxolitinib inhibits phosphorylation of JAK and STAT proteins

Administration of 200 nM ruxolitinib caused a significant reduction in the expression of JAK1 and JAK2 as well as a decrease in the level of p-JAK1 and p-JAK2 (reduced by 0.49 and 0.38 times, respectively). Expression of STAT3 was not significantly affected by ruxolitinib; however, the level of p-STAT1 and p-STAT3 were decreased by 0.48 and 0.58-fold, respectively, in response to administration of ruxolitinib compared with the control (Fig. 4).

DISCUSSION

GBM is well known for its highly vascularized and invasive nature. The invasion into neighboring parenchyma often limits the success of treatment

21,22. The hypoxic microenvironment which is included in the glioma invasion leads to driving tumor growth. Although the development of approaches to prevent glioma invasion is of high clinical importance, the involvement of multiple molecular players in the molecular mechanisms—including transcription activators, kinases, and microRNAs—makes this a challenging field. The present study is, to the best of our knowledge, the first to demonstrate the effects of ruxolitinib on the IFNs dependent JAK/STAT signaling pathway in glioblastomas.

Ruxolitinib (INCB018424) is an oral tyrosine kinase inhibitor which selectively inhibits JAK. It has been approved for clinical use by the Food and Drug Administration for treatment of conditions including myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocytopenia myelofibrosis

21. In recent years, preclinical studies have sug-

Fig. 4. A: JAK/STAT-IFNAR and JAK/STAT-IFN-γ receptor signaling pathway. B: Western blot analysis demonstrated the relative expressions of active JAK1, Phospho-JAK1 (p Y1022+Y1023), JAK2, Phospho-JAK2 (p Tyr1007, Tyr1008), Phospho-STAT1 [p Tyr701], STAT3, Phospho-STAT3 (p Tyr705), SOCS7 and β-actin in the 50, 100, and 200 nM ruxolitinib treated and untreated (control=1) U87 spheroids. CM : cell membrane, NM : nuclear membrane, JAK/STAT : Janus kinase-signal transducer and activator of transcription, IFNAR : interferon alpha receptor, IFN : interferon, SOCS : the suppressor of cytokine signalling.
gested that ruxolitinib may have anti-glioma activities. Wei et al.\(^{31}\) reported the effect of ruxolitinib on human medulloblastoma cells. In our previous study, we found that single-dose ruxolitinib (195 nM) inhibited glioma invasion via disruption of the IL-6 dependent JAK2/STAT3 pathway, and also significantly affected miR-20a and miR-17 expression\(^6\). Furthermore, Haile et al.\(^{11}\) demonstrated that ruxolitinib can cross the blood-brain barrier of mice. Together, the data suggest that ruxolitinib is an ideal candidate chemotherapeutic agent for the treatment of GBM.

The type I IFNs, IFN-\(\alpha\) and \(\beta\), are involved in the innate immune response, while IFN-\(\gamma\) denoted type II IFNs, has antitumor effects beyond its involvement in the immune system.\(^{25}\) Type I IFNs have two receptors, IFNAR1 and 2. Both IFN-\(\gamma\)R1 and 2 are receptors of IFN-\(\gamma\). Downstream signaling of IFNs activates the JAK/STAT signaling pathway, which involves phosphorylation of STAT proteins. The subsequent dimerization of activated (phosphorylated) STAT causes these proteins to migrate to the nucleus, where p-STAT proteins then induce expression of IFN-stimulated genes (see Fig. 4 for details). Ultimately, IFNs can activate members of the STAT family such as STAT1, STAT2, STAT3, STAT4, and STAT5, which then induce expression of IFN-stimulated genes (see Fig. 4 for details). The products of JAK/STAT signaling pathway genes have been reported to be associated with glioma invasion, and many inhibitors have been evaluated for their utility in the treatment of GBM through \textit{in vitro} and \textit{in vivo} experiments involving blockade of this signaling pathway.\(^{13,16,20,22}\) Previous studies revealed the antitumor effects of IFNs toward glioma, and the strong inhibitory effects of IFNs toward glioma invasion have been demonstrated \textit{in vitro}.\(^{2,8,9}\) Moreover, in a clinical study, IFN-\(\beta\) has been trialed as a combination therapy with temozolomide for high-grade glioma.\(^{40}\) Our results of IFN-\(\alpha\) and IFN-\(\gamma\) expression in response to ruxolitinib, as well as that of IFNAR2 and IFNAR1 and the decreased invasion of glioblastoma cancer spheroids, suggest that IFNs may play a pivotal role in glioma invasion. This supports the results of previous studies.\(^{20,8,28}\)

Hypoxia-inducible factors are master regulators of oxygen concentration homeostasis. These proteins consist of two subunits, HIF-1\(\alpha\) and HIF-1\(\beta\), with HIF-1\(\alpha\) representing the functional part of the complex and HIF-1\(\beta\) exhibiting no known functions\(^{21}\). Hypoxia is an important stimulus for angiogenesis, as overexpression of HIF-1\(\alpha\) activates VEGF. According to the literature, angiogenesis is an independent predictor of poor prognosis for GBM, and both HIF-1\(\alpha\) and VEGF are strongly associated with angiogenesis in GBM.\(^{13,15}\) In the present study, inhibition of IFN activated the JAK/STAT signaling pathway, indicated by the dose-dependent decrease in glioma invasion in response to ruxolitinib (Fig. 1A). However, the results of HIF-1\(\alpha\) expression in response to ruxolitinib suggest that ruxolitinib may have an inhibitory effect on glioma invasion which is affected via JAK/STAT signaling, but not through changes in the expression profiles of HIF and VEGF. As it is well known that activation of the HIF-1 pathway is a common feature of the mechanism underlying gliomagenesis,\(^{1,17}\) we believe that the factors and pathways involved in the regulation of oxygen metabolism in gliomagenesis are complex, and further research is needed to fully elucidate the mechanisms involved.

Our analyses of expression profiles of STAT proteins, as well as SOCS3, 5, and 7 in combination with Western blot results revealed that inhibition of phosphorylation of key proteins in the JAK/STAT pathway in glioblastoma tumor spheroids are affected by ruxolitinib in a dose-dependent manner. Based on this, our data suggest that ruxolitinib can inhibit glioma invasion via the IFN receptor-dependent JAK/STAT signaling pathway.

**CONCLUSION**

In conclusion, our results highlight the important inhibitory effects of ruxolitinib in glioma invasion, and provide evidence of a mechanism involving the IFN-dependent JAK/STAT signaling pathway but not through changes to the HIF and VEGF expression. These findings suggest that inhibition of this pathway may act synergistically to improve the poor prognosis of this disease. Few studies have been carried out on this subject, and there is little in the way of definitive evidence. For this reason, further detailed studies are needed.

**CONFLICTS OF INTEREST**

No potential conflict of interest relevant to this article was reported.
Ruxolitinib Inhibits JAK/STAT Signalling | Delen E, et al.

INFORMED CONSENT

This type of study does not require informed consent.

AUTHOR CONTRIBUTIONS

Conceptualization : ED, OD
Data curation : ED, OD
Formal analysis : ED, OD
Funding acquisition : ED, OD
Methodology : ED, OD
Project administration : ED, OD
Visualization : ED, OD
Writing - original draft : ED, OD
Writing - review & editing : ED, OD

ORCID

Emre Delen https://orcid.org/0000-0001-5573-9492
Oğuzhan Doğanlar https://orcid.org/0000-0003-2654-7269

Acknowledgements

This research was supported by a grant from the Trakya University Scientific Research (TUBAP-2018/155). This study was supported by a grant from Turkish Neurosurgical Society, Ankara, Turkey.

References

1. Atkinson GP, Nozell SE, Benveniste ETN : NF-kappaB and STAT3 signaling in glioma: targets for future therapies. Expert Rev Neurother 10 : 575-586, 2010
2. Batash R, Asna N, Schaffer P, Francis N, Schaffer M : Glioblastoma multiforme, diagnosis and treatment; recent literature review. Curr Med Chem 24 : 3002-3009, 2017
3. Charras A, Arvaniti P, Le Dantec C, Arleevskaya MI, Zachou K, Dalekos GN, et al. : JAK inhibitors suppress innate epigenetic reprogramming: a promise for patients with Sjögren’s syndrome. Clin Rev Allergy Immunol 58 : 182-193, 2020
4. Cheng Z, Fu J, Liu G, Zhang L, Xu Q, Wang SY : Angiogenesis in JAK2 V617F positive myeloproliferative neoplasms and ruxolitinib decrease VEGF, HIF-1 enesis in JAK2 V617F positive cells. Leuk Lymphoma 59 : 196-203, 2018
5. Clara CA, Marie SK, de Almeida JR, Wakamatsu A, Obá-Shinjo SM, Uno M, et al. : Angiogenesis and expression of PDGF-C, VEGF, CD105 and HIF-1a in human glioblastoma. Neuropathology 34 : 343-352, 2014
6. Delen E, Doganlar O, Doganlar ZB, Delen O : Inhibition of the invasion of human glioblastoma U87 cell line by ruxolitinib: a molecular player of miR-17 and miR-20a regulating JAK/STAT pathway. Turk Neurosurg 30 : 182-189, 2020
7. Del Duca D, Werbowetski T, Del Maestro RF : Spheroid preparation from hanging drops: characterization of a model of brain tumor invasion. J Neurooncol 67 : 295-303, 2004
8. Fetell MR, Hausepian EM, Oster MW, Cote DN, Sisti MB, Marcus SG, et al. : Intratumor administration of beta-interferon in recurrent malignant gliomas. A phase I clinical and laboratory study. Cancer 65 : 78-83, 1990
9. Fogelman D, Cubillo A, García-Alfonso P, Mirón MLL, Nemunaitis J, Flora D, et al. : Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer. Cancer Med 7 : 5382-5393, 2018
10. George J, Banki NL, Ray SK : Knockdown of hTERT and concurrent treatment with interferon-gamma inhibited proliferation and invasion of human glioblastoma cell lines. Int J Biochem Cell Biol 42 : 1164-1173, 2010
11. Haile WB, Gavegnano C, Tao S, Jiang Y, Schirazi RF, Tyor WR : The Janus kinase inhibitor ruxolitinib reduces HIV replication in human macrophages and ameliorates HIV encephalitis in a murine model. Neurobiol Dis 92(Pt B) : 137-143, 2016
12. Han ES, Wen W, Dellinger TH, Wu J, Lu SA, Jove R, et al. : Ruxolitinib synergistically enhances the anti-tumor activity of paclitaxel in human ovarian cancer. Cancer Sci 108 : 520-527, 2017
13. Honda S, Sadatomi D, Yamamura Y, Nakashioya K, Tanimura S, Takeda K : WP1066 suppresses macrophage cell death induced by inflamma-some agonists independently of its inhibitory effect on STAT3. Cancer Sci 108 : 650-657, 2017
14. Hurwitz HI, Uppal N, Wagner SA, Bendell JC, Beck JT, Wade SM 3rd, et al. : Randomized, double-blind, phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed. J Clin Oncol 33 : 4039-4047, 2015
15. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Batchelor TT : Inhibition with interferon-gamma inhibited proliferation and invasion of human glioblastoma cell lines. Int J Biochem Cell Biol 42 : 1164-1173, 2010
16. Jensen KV, Cseh O, Aman A, Weiss S, Luchman HA : The JAK2/STAT3 initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model. PLoS One 12 : e0198670, 2017
17. Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, Van Meir EG : Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol 7 : 134-153, 2005
18. Kim EK, Chung DS, Shin HJ, Hong YK : Inhibitory effect of IFN-beta, on the Antitumor activity of celecoxib in U87 glioma model. J Korean Neurosurg Soc 63 (4) : 444-454, 2018
19. Knüpfer MM, Knüpfer H, Van Gool S, Domula M, Wolff JE: Interferon gamma inhibits proliferation and hyaluronic acid adhesion of human malignant glioma cells in vitro. *Cytokine* **12**: 409-412, 2000
20. Li H, Liang Q, Wang L: Icaritin inhibits glioblastoma cell viability and glycolysis by blocking the IL-6/Stat3 pathway. *J Cell Biochem* **120**: 7257-7264, 2019
21. Loboda A, Jozkowicz A, Dulak J: HIF-1 and HIF-2 transcription factors - similar but not identical. *Mol Cells* **29**: 435-442, 2010
22. Mukthavaram R, Ouyang X, Saklecha R, Jiang P, Nomura N, Pingle SC, et al.: Effect of the JAK2/STAT3 inhibitor SAR317461 on human glioblastoma tumorspheres. *J Transl Med* **13**: 269, 2015
23. Ohno M, Natsume A, Kondo Y, Iwamizu H, Motomura K, Toda H, et al.: The modulation of microRNAs by type I IFN through the activation of signal transducers and activators of transcription 3 in human glioma. *Mol Cancer Res* **7**: 2022-2030, 2009
24. Price SJ, Gillard JH: Imaging biomarkers of brain tumour margin and tumour invasion. *Br J Radiol* **84 Spec No 2**: S159-S167, 2011
25. Priyanka R, Muralidharan NP: Interferons and interferon therapy. *J Pharm Sci Res* **6**: 400-403, 2014
26. Schneider CA, Rasband WS, Eliceiri KW: NIH Image to ImageJ: 25 years of image analysis. *Nat Methods* **9**: 671-675, 2012
27. Silginer M, Nagy S, Hoppold C, Schneider H, Weller M, Roth P: Autocrine activation of the IFN signaling pathway may promote immune escape in glioblastoma. *Neuro Oncol* **19**: 1338-1349, 2017
28. Tate MC, Aghi MK: Biology of angiogenesis and invasion in glioma. *Neurotherapeutics* **6**: 447-457, 2009
29. Vallatos A, Al-Mubarak HFI, Birch JL, Gaillagher L, Mullin JM, Gilmour L, et al.: Quantitative histopathologic assessment of perfusion MRI as a marker of glioblastoma cell infiltration in and beyond the peritumoral edema region. *J Magn Reson Imaging* **50**: 529-540, 2019
30. Wakabayashi T, Kayama T, Nishikawa R, Takahashi H, Hashimoto N, Takahashi J, et al.: A multicenter phase I trial of combination therapy with interferon-β and temozolomide for high-grade gliomas (INTEGRA study): the final report. *J Neurooncol* **104**: 573-577, 2011
31. Wei J, Ma L, Li C, Pierson CR, Finlay JL, Lin J: Targeting upstream kinases of STAT3 in human medulloblastoma cells. *Curr Cancer Drug Targets* **19**: 571-582, 2019
32. Weiswald LB, Bellet D, Dangles-Marie V: Spherical cancer models in tumor biology. *Neoplasia* **17**: 1-15, 2015